Thursday, 23 June 2022

08.30 – 08.45  Registration
08.45 – 09.00  Introduction – Jan van Meerbeeck, BE and Annemiek Snoeckx, BE

Session 1: Update on lung cancer screening: did we make any further progress?
Chair: Annemiek Snoeckx, BE

09.00 – 09.30  European agenda on lung cancer screening – Brian Ward (ERS), BE
09.30 – 10.00  Four years after NELSON: Are there any further data on subgroup analyses or secondary endpoints? – Harry De Koning, NL
10.00 – 10.30  Implementing lung cancer screening in Europe: taking a systems approach – Suzanne Wait (The Health Policy Partnership), UK

10.30 – 11.00  Coffee break

11.00 – 12.45  Break-out session 1 (whole group): What is currently ongoing in Europe?
Chair: Jan van Meerbeeck, BE
  •  An update on current initiatives in different European countries (tbc)

12.45 – 13.30  Lunch break

Session 2: Hurdles and barriers in implementation
Chair: TBC

14.00 – 14.30  Psychological impact of lung cancer screening – Georgia Hardavella, GR
14.30 – 15.00  The voice of the participant – Janette Rawlinson, UK

15.00 – 16.30  Break out session 2: Challenges for implementation
•  Group 1: Targeting the hard to reach (Chair: Samantha Quaife, UK)
•  Group 2: How will smoking cessation be integrated into your lung cancer screening program? (Chair: tbc)

16.30 – 17.00  Coffee break
Session 3: The world does not stand still: evolution in diagnosis and treatment
Chair: TBC

17.00 – 17.30 Is ultra-low-dose ready for practice? – TBC
17.30 – 18.00 Research opportunities in nodule handling: robotic surgery and beyond – Witold Rzyman, PL
18.00 – 18.30 Artificial Intelligence in lung cancer screening – Colin Jacobs, NL

20.00 Dinner

Friday, 24 June 2022

Session 4: Early detection biomarkers: ready for implementation in screening?
Chair: TBC

09.00 – 09.30 Genomic screening: myths, promises and achievements – Joanna Chorostowska, PL
09.30 – 10.00 Biomarker performance and pathways to clinical utility – Luis M. Montuenga, ES
10.00 – 10.30 Reimaging diagnostic test development - harnessing the power of combination biomarkers – TBC

10.30 – 11.00 Coffee break

11.00 – 11.40 Report from break out session II
  • Group 1 + discussion 20’ Chair: Samantha Quaife, UK
  • Group 2 + discussion 20’ Chair: TBC

Session 5: Taking research forward in the EU
Chair: Annemiek Snoeckx, BE

11.40 – 12.10 What is the optimal design for trials incorporating biomarkers and CT-scan screening? – Hilary Robbins, FR
12.10 – 12.40 The ERS and ongoing and planned task forces and EU projects – Torsten Blum, DE
12.40 – 13.00 Remarks, wrap up and action points – Jan van Meerbeeck and Annemiek Snoeckx, BE
13.00 – 14.00 Lunch